This study aimed to evaluate the potential prognostic value of CTSE to predict progression to more advanced disease in patients with Barrett metaplasia–dysplasia–adenocarcinoma spectrum, and to predict survival for patients with EAC. This evidence concerns the gene CTSE and adenocarcinoma.